PUBLIC COMPANY
save$ZYMEZymeworks Inc.
$ZYME25.12-2.48%Middletown, DE, USupdated 6h ago
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 9, 26grantSchayowitz Adam · See Remarks70,000 sh
- Apr 9, 26grantSchayowitz Adam · See Remarks47,000 sh
- Apr 9, 26grantSchayowitz Adam · See Remarks76,000 sh
- Apr 9, 26grantPlatshon Scott · EVP, Chief Business Officer70,000 sh
- Apr 9, 26grantPlatshon Scott · EVP, Chief Business Officer47,000 sh
- Apr 9, 26grantPlatshon Scott · EVP, Chief Business Officer76,000 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- BioMarin discontinues rare disease drug; CSL and Arcturus split upBioMarin drops rare disease asset after mixed Phase 3: BioMarin decided to discontinue development of BMN401, an enzyme replacement therapy for ENPP1 deficiency, the biotech said as part of its sec…endpoints · 7d ago
- Intellia identifies genetic risk factor for liver complications in CRISPR trialIntellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis. The g…endpoints · 8d ago
- FDA warns Genzyme's Irish site over quality questionsAn FDA warning letter sent late last month to Genzyme's Ireland-based manufacturing site, now owned by Sanofi, raises significant quality- and data-related issues. On data integrity, the warning le…endpoints · 1mo ago
- Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe diseaseSanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US. The French pharma is looking to…endpoints · 1mo ago
- BioMarin's rare disease therapy shows no clinical benefit in Phase 3 testBioMarin’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results in a late-stage study. Patients with the condition don't produce enough of the ENPP…endpoints · 2mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that